RefleXion Appoints Jeff Holifield, J.D. as Vice President and Head of Legal
January 20, 2021
HAYWARD, Calif., Jan. 20, 2021 – RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced the appointment of Jeff Holifield, J.D. as vice president and head of legal effective immediately. Holifield will report directly to President and Chief Executive Officer, Todd Powell.
“Jeff joins RefleXion as a highly regarded legal executive with expertise in innovative business models, compliance and corporate governance, having operated in multiple complex business environments,” said Powell. “As we ramp our commercialization, his experience in supporting the legal needs of high growth companies will be a tremendous asset to RefleXion, and we are honored to have him join our team.”
Holifield has worked in the technology sector for over 25 years, with a focus on SaaS licensing, cloud-based services, marketing partnerships, regulatory compliance, manufacturing, and supply chain issues. He joins RefleXion from Nutanix, a leader in cloud computing, where he was associate general counsel in charge of leading the legal transition from a hardware model to a subscription model. Before his tenure at Nutanix, Holifield held senior legal services positions at Microsoft, Ericsson, Sun Microsystems, Sony Electronics and CenturyLink. He holds a J.D. from the University of Washington, School of Law, and a Bachelor of Arts in Political Science from Whitman College.
“I’m thrilled to be joining RefleXion, a disruptive company that is truly making a difference in cancer care and poised for significant growth,” said Holifield. “I look forward to working with the team at RefleXion in support of the company’s vision of providing leading-edge treatment for all cancer patients, even those with late-stage disease.”
The RefleXion™ X1 machine with BgRT is designed to overcome the technical limitations that restrict radiotherapy to one or two tumors. Instead, it will one day allow radiotherapy to reach multiple tumors during the same treatment session, including tumors that move due to patient motion, such as breathing or digestion.
About RefleXion Medical
RefleXion is a privately held therapeutic oncology company developing the first biology-guided radiotherapy (BgRT) machine, with the potential to move beyond single tumor therapy to one day treat multiple metastatic tumors throughout the body in the same treatment session. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
*The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to Investigational use.
Media Contact
Amy Cook
acook@reflexion.com
925-200-2125
